RS63832B1 - Niraparib, abirateron acetat i prednizon za lečenje raka prostate - Google Patents
Niraparib, abirateron acetat i prednizon za lečenje raka prostateInfo
- Publication number
- RS63832B1 RS63832B1 RS20221127A RSP20221127A RS63832B1 RS 63832 B1 RS63832 B1 RS 63832B1 RS 20221127 A RS20221127 A RS 20221127A RS P20221127 A RSP20221127 A RS P20221127A RS 63832 B1 RS63832 B1 RS 63832B1
- Authority
- RS
- Serbia
- Prior art keywords
- niraparib
- prednisone
- abiraterone acetate
- day
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762485164P | 2017-04-13 | 2017-04-13 | |
| PCT/US2018/026661 WO2018191141A1 (en) | 2017-04-13 | 2018-04-09 | Combination therapy for prostate cancer |
| EP18720895.4A EP3609497B1 (en) | 2017-04-13 | 2018-04-09 | Niraparib, abiraterone acetate and prednisone for treating prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS63832B1 true RS63832B1 (sr) | 2023-01-31 |
Family
ID=62067858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20221127A RS63832B1 (sr) | 2017-04-13 | 2018-04-09 | Niraparib, abirateron acetat i prednizon za lečenje raka prostate |
Country Status (33)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119606965A (zh) | 2016-07-29 | 2025-03-14 | 詹森药业有限公司 | 治疗前列腺癌的方法 |
| WO2020139339A1 (en) * | 2018-12-27 | 2020-07-02 | Constellation Pharmaceuticals, Inc. | Ezh2 and androgen receptor signaling inhibitors as tools for targeting prostate cancer |
| CN110538150A (zh) | 2019-09-26 | 2019-12-06 | 湖南瑞林医药科技有限公司 | 一种含有醋酸阿比特龙的药物组合物及其制备方法和应用 |
| JP7442328B2 (ja) * | 2020-02-03 | 2024-03-04 | 株式会社三共 | 遊技機 |
| CN113546037B (zh) * | 2020-04-20 | 2024-12-27 | 鲁南制药集团股份有限公司 | 一种醋酸阿比特龙栓剂及其制备方法 |
| AU2021269115A1 (en) * | 2020-05-08 | 2023-01-19 | Janssen Pharmaceutica Nv | Treatment of prostate cancer with a combination of abiraterone acetate and niraparib |
| KR20230159510A (ko) * | 2021-03-24 | 2023-11-21 | 화이자 인코포레이티드 | Ddr 유전자 돌연변이된 전이성 거세-감수성 전립선암의 치료를 위한 탈라조파립과 항안드로겐의 조합 |
| CN114306236B (zh) * | 2021-12-15 | 2022-10-21 | 湖南慧泽生物医药科技有限公司 | 用于负载醋酸阿比特龙的自微乳体系及组合物和应用 |
| TWI828471B (zh) | 2021-12-15 | 2024-01-01 | 大陸商湖南慧澤生物醫藥科技有限公司 | 醋酸阿比特龍的自微乳組合物和應用 |
| CN118973555A (zh) * | 2022-04-07 | 2024-11-15 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的组合疗法 |
| WO2024203348A1 (ja) * | 2023-03-31 | 2024-10-03 | ソニーグループ株式会社 | 腫瘍の解析方法、腫瘍の解析システム、及び腫瘍の解析データ生成方法 |
| WO2025027138A1 (en) * | 2023-08-02 | 2025-02-06 | Janssen Pharmaceutica Nv | Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080051380A1 (en) * | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
| PL2061561T3 (pl) * | 2006-08-25 | 2013-12-31 | Janssen Oncology Inc | Kompozycje do leczenia raka |
| EA016079B1 (ru) | 2007-01-10 | 2012-01-30 | Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа | Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp) |
| NZ586675A (en) | 2008-01-08 | 2012-04-27 | Merck Sharp & Dohme | Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide |
| WO2012009475A1 (en) * | 2010-07-14 | 2012-01-19 | Oregon Health & Science University | Methods of treating cancer with inhibition of lysine-specific demethylase 1 |
| US9314473B2 (en) * | 2011-02-03 | 2016-04-19 | Pop Test Oncology Limited Liability Company | System and method for diagnosis and treatment |
| WO2014089324A1 (en) * | 2012-12-07 | 2014-06-12 | Calitor Sciences, Llc | Substituted cyclic compounds and methods of use |
-
2018
- 2018-04-09 EA EA201992430A patent/EA201992430A1/ru unknown
- 2018-04-09 JP JP2019555852A patent/JP7141408B2/ja active Active
- 2018-04-09 JO JOJO/P/2019/0244A patent/JOP20190244B1/ar active
- 2018-04-09 HU HUE18720895A patent/HUE060460T2/hu unknown
- 2018-04-09 IL IL269879A patent/IL269879B2/en unknown
- 2018-04-09 CN CN202411589875.XA patent/CN119235874A/zh active Pending
- 2018-04-09 DK DK18720895.4T patent/DK3609497T3/da active
- 2018-04-09 SM SM20220467T patent/SMT202200467T1/it unknown
- 2018-04-09 KR KR1020197032257A patent/KR20190134718A/ko not_active Ceased
- 2018-04-09 WO PCT/US2018/026661 patent/WO2018191141A1/en not_active Ceased
- 2018-04-09 MY MYPI2023006196A patent/MY209010A/en unknown
- 2018-04-09 MA MA48728A patent/MA48728B1/fr unknown
- 2018-04-09 EP EP22200882.3A patent/EP4176879A1/en not_active Withdrawn
- 2018-04-09 KR KR1020267009381A patent/KR20260048358A/ko active Pending
- 2018-04-09 ES ES18720895T patent/ES2931052T3/es active Active
- 2018-04-09 AU AU2018251594A patent/AU2018251594A1/en not_active Abandoned
- 2018-04-09 PL PL18720895.4T patent/PL3609497T3/pl unknown
- 2018-04-09 EP EP22200801.3A patent/EP4176878A1/en active Pending
- 2018-04-09 CA CA3059562A patent/CA3059562A1/en active Pending
- 2018-04-09 PT PT187208954T patent/PT3609497T/pt unknown
- 2018-04-09 MX MX2019012296A patent/MX2019012296A/es unknown
- 2018-04-09 CR CR20190467A patent/CR20190467A/es unknown
- 2018-04-09 IL IL320452A patent/IL320452A/en unknown
- 2018-04-09 PE PE2019002030A patent/PE20200444A1/es unknown
- 2018-04-09 MD MDE20200190T patent/MD3609497T2/ro not_active IP Right Cessation
- 2018-04-09 UA UAA201911057A patent/UA129514C2/uk unknown
- 2018-04-09 EP EP18720895.4A patent/EP3609497B1/en active Active
- 2018-04-09 LT LTEPPCT/US2018/026661T patent/LT3609497T/lt unknown
- 2018-04-09 SG SG11201909552V patent/SG11201909552VA/en unknown
- 2018-04-09 CN CN201880039365.1A patent/CN110753545A/zh active Pending
- 2018-04-09 RS RS20221127A patent/RS63832B1/sr unknown
- 2018-04-09 HR HRP20221327TT patent/HRP20221327T1/hr unknown
- 2018-04-11 US US15/950,707 patent/US20180296574A1/en active Pending
-
2019
- 2019-10-08 CL CL2019002871A patent/CL2019002871A1/es unknown
- 2019-10-09 NI NI201900105A patent/NI201900105A/es unknown
- 2019-10-10 PH PH12019502317A patent/PH12019502317A1/en unknown
- 2019-10-14 MX MX2023009569A patent/MX2023009569A/es unknown
- 2019-10-14 DO DO2019000264A patent/DOP2019000264A/es unknown
- 2019-10-18 CO CONC2019/0011591A patent/CO2019011591A2/es unknown
-
2022
- 2022-02-25 US US17/680,553 patent/US20220175801A1/en not_active Abandoned
- 2022-07-22 JP JP2022117192A patent/JP7407880B2/ja active Active
-
2023
- 2023-07-13 JO JOJO/P/2023/0159A patent/JOP20230159A1/ar unknown
- 2023-11-20 JP JP2023196574A patent/JP2024023344A/ja active Pending
-
2024
- 2024-02-01 US US18/429,778 patent/US20240245710A1/en active Pending
- 2024-04-11 AU AU2024202346A patent/AU2024202346B2/en active Active
- 2024-08-09 US US18/799,339 patent/US20240398837A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240398837A1 (en) | Combination Therapy For Prostate Cancer | |
| US20260041695A1 (en) | Combination therapies for treatment of breast cancer | |
| JP2024510612A (ja) | ソトラシブ投与レジメン | |
| EP4340842B1 (en) | Sotorasib for use in the treatment of cancer | |
| JP2022518235A (ja) | 進行期固形腫瘍がんの治療用ｒｎａ | |
| HK40092155A (en) | Combination therapy for prostate cancer | |
| AU2022341107A1 (en) | Sotorasib and an egfr antibody for treating cancer comprising a kras g12c mutation | |
| EA044835B1 (ru) | Комбинированная терапия рака предстательной железы | |
| EA052155B1 (ru) | Комбинированная терапия рака предстательной железы | |
| Reichardt et al. | Clinical experience to date with nilotinib in gastrointestinal stromal tumors | |
| BR122022022077B1 (pt) | Combinação e composição compreendendo niraparibe, acetato de abiraterona, e prednisona, seu uso para tratar câncer de próstata e kit | |
| BR112019021466B1 (pt) | Composição compreendendo niraparibe, acetato de abiraterona, e prednisona, bem como uso dos referidos compostos | |
| EP4665725A2 (en) | Methods of treating solid tumors with mitogen activated protein kinase (mapk) pathway alterations | |
| KR20260006644A (ko) | 유방암 치료에 사용하기 위한 카피바서티브, cdk4/6 억제제 및 풀베스트란트의 조합 | |
| HUSSAIN | Androgen Receptor Axis Targeting in the Treatment |